Patents Assigned to Dana-Farber Cancer Institute
  • KDM INHIBITORS AND USES THEREOF
    Publication number: 20220348563
    Abstract: Provided herein are compounds that inhibit histone lysine demethylase (KDM) and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and methods of treating or preventing diseases (e.g., proliferative diseases, e.g., cancer). In certain embodiments, the compounds described herein are represented by formulas (I) and (II).
    Type: Application
    Filed: September 10, 2020
    Publication date: November 3, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Paul M. Park, Chengkui Pei, Xiaofeng Zhang
  • MICROGLIA SPECIFIC PROMOTERS AND METHODS OF USE THEREFORE
    Publication number: 20220348962
    Abstract: The present disclosure features methods and compositions for expressing transgenes in microglia. The disclosed compositions comprise isolated fragments of human and murine translocator protein (TSPO) promoters and expression cassettes comprising the same. The methods involve using these promoters and/or expression cassettes to express transgenes in a cell.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 3, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Valentina POLETTI, Marco PEVIANI, Francisco J. MOLINA-ESTEVEZ
  • Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
    Patent number: 11485787
    Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: November 1, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Boston Children's Hospital
    Inventors: Rosemarie Dekruyff, Gordon J. Freeman, Dale Umetsu, Sanhong Yu, Yanping Xiao
  • RAPID PREDICTION OF DRUG RESPONSIVENESS
    Publication number: 20220340976
    Abstract: The present disclosure relates to compositions and methods for rapid prediction, based upon early single cell transcriptomic assessment of a biopsied sample obtained from a subject, of whether a subject will be responsive to a drug.
    Type: Application
    Filed: September 1, 2020
    Publication date: October 27, 2022
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Andrew J. Aguirre, Francisca Vazquez, Aviad Tsherniak, James McFarland, Brenton Paolella
  • Methods for genome characterization
    Patent number: 11479878
    Abstract: The invention provides methods of using low coverage sequencing to assess the relative fraction of tumor versus normal DNA in a sample, and to assess copy number alterations present in the sample.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 25, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gavin Ha, Viktor Adalsteinsson, Samuel Freeman
  • CRISPR EFFECTOR SYSTEM BASED MULTIPLEX CANCER DIAGNOSTICS
    Publication number: 20220333208
    Abstract: Systems and methods for rapid diagnostics related to the use of CRISPR effector systems and optimized guide sequences, including multiplex lateral flow diagnostic devices and methods of use, including for detection of cancer markers, are provided.
    Type: Application
    Filed: September 3, 2020
    Publication date: October 20, 2022
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jonathan Gootenberg, Omar Abudayyeh, Jeremy Koob, Rahul Vedula, Coleman Lindsley, Feng Zhang
  • METHODS AND COMPOSITIONS FOR RECONSTITUTING MICROGLIA
    Publication number: 20220323503
    Abstract: The present disclosure features CX3CR1 hemizygous and/or homozygous defective cells and methods of using such cells for the treatment of a metabolic or neurological disorder. The disclosed methods include methods for making and modifying CX3CR1 hemizygous and/or homozygous defective cells, such as hematopoietic stem progenitor cells. Other disclosed methods include methods of treating a subject having or suspected of having a metabolic or neurological disease comprising administering to the subject a composition comprising a hemizygous and/or homozygous defective CX3CR1 cell. The CX3CR1 hemizygous and/or homozygous defective cell may be modified to have a nucleic acid molecule encoding a therapeutic polypeptide or polynucleotide.
    Type: Application
    Filed: August 6, 2020
    Publication date: October 13, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Annita MONTEPELOSO
  • Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
    Patent number: 11466064
    Abstract: Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: October 11, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Rosalind Segal, Loren D. Walensky, Lisa Vaughn Goodrich, Sarah Elizabeth Raissi, Maria F. Murphy, Gregory H. Bird
  • USP7 inhibitors for treating multiple myeloma
    Patent number: 11465983
    Abstract: The present disclosure relates to inhibitors of USP7 useful in the treatment of cancers, and other USP7 mediated diseases, having the Formula: wherein R1, R2, R3, R4, R5, R6, and n are described herein.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: October 11, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Sara Buhrlage, Kenneth C. Anderson, Dharminder Chauhan, Sirano Dhe-Paganon, Xiaoxi Liu, Hyuk-Soo Seo
  • Monoclonal antibodies that bind human CD161
    Patent number: 11459389
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: October 4, 2022
    Assignees: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Karl Dane Wittrup, Kai Wucherpfennig, Byong Ha Kang, Nathan D. Mathewson
  • USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING
    Publication number: 20220305048
    Abstract: Disclosed herein are methods for treating a subject having cancer by coadministering a stimulator of interferon signaling and a heparin polysaccharide. Also disclosed herein are pharmaceutical compositions that include a stimulator of interferon signaling and a heparin polysaccharide.
    Type: Application
    Filed: August 26, 2020
    Publication date: September 29, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Shriram Sundararaman, Erik Knelson, Shunsuke Kitajima, David Barbie, Saemi Han
  • USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS
    Publication number: 20220305016
    Abstract: The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).
    Type: Application
    Filed: January 21, 2022
    Publication date: September 29, 2022
    Applicants: The General Hospital Corporation, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Marc Wein, Henry Kronenberg, Thomas Sundberg, Ramnik Xavier, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Alykhan Shamji
  • DNA NANOSTRUCTURE-BASED VACCINES
    Publication number: 20220305119
    Abstract: Provided herein, in some embodiments, are nucleic acid nanostructure-based vaccines.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 29, 2022
    Applicants: Dana-Farber Cancer Institute, Inc., Korea Institute of Science and Technology
    Inventors: William M. Shih, Ju Hee Ryu, Yang Zeng
  • Combination therapy with neoantigen vaccine
    Patent number: 11452768
    Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 27, 2022
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine J. Wu, Edward F. Fritsch
  • Immunomodulation by IAP Inhibitors
    Publication number: 20220296581
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 22, 2022
    Applicants: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS
    Publication number: 20220298157
    Abstract: Compounds of formula (I), formula (I), processes for their production and their R use as pharmaceuticals.
    Type: Application
    Filed: April 22, 2020
    Publication date: September 22, 2022
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
  • IMMUNE SIGNATURES PREDICTIVE OF RESPONSE TO PD-1 BLOCKADE IN RICHTER'S TRANSFORMATION
    Publication number: 20220298580
    Abstract: The present invention relates to methods for identifying Richter's transformation patients who benefit from PD-1 blockade.
    Type: Application
    Filed: August 27, 2020
    Publication date: September 22, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Catherine Wu, Erin Parry
  • Compounds for the degradation of STK4 and treatment of hematologic malignancies
    Patent number: 11447467
    Abstract: The application relates to a compound of Formula (I) which modulate the amount of STK4, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of STK4.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 20, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Sara Buhrlage, Kenneth C. Anderson, Teru Hideshima, Nathanael S. Gray, Xiaoxi Liu
  • Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
    Patent number: 11446309
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 20, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
    Patent number: 11447559
    Abstract: Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 20, 2022
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Hye-Ji Choi, Jae-Chan Park, Hyung-Kwon Lim